An in vitro study on 3T3-L1 adipocytes showed that Guduchi Glyco One effectively inhibits adipogenesis and reduces lipid accumulation. The formulation demonstrated superior efficacy compared to Metformin, while the combination of Glyco One and Metformin exhibited the strongest anti-adipogenic effect.

An in vitro study was conducted to investigate the anti-diabetic activity of Guduchi Glyco DN in HepG2 cells. The formulation was found to be safe up to 250 µg/mL and significantly improved insulin signaling by enhancing AKT phosphorylation under high-glucose conditions, demonstrating its potential to reduce insulin resistance.

Guduchi Glyco NKT was evaluated for its anti-diabetic activity using liver and pancreatic cell models. The formulation showed minimal cytotoxicity in HepG2 cells and enhanced insulin secretion in INS-1E cells. The observed effects indicate its potential role in improving pancreatic β-cell function and supporting diabetes management.

In-vitro studies demonstrated that Guduchi GLYCO One is safe and effectively enhances glucose uptake in skeletal muscle cells. The formulation showed greater glucose uptake than insulin under the experimental conditions, highlighting its potential in improving insulin sensitivity and glucose metabolism.